{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Inducteurs du cytochrome P-450 CYP2C9 : Questions médicales les plus fréquentes",
"headline": "Inducteurs du cytochrome P-450 CYP2C9 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Inducteurs du cytochrome P-450 CYP2C9 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-07",
"dateModified": "2025-04-01",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Inducteurs du cytochrome P-450 CYP2C9"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Inducteurs des enzymes du cytochrome P-450",
"url": "https://questionsmedicales.fr/mesh/D065693",
"about": {
"@type": "MedicalCondition",
"name": "Inducteurs des enzymes du cytochrome P-450",
"code": {
"@type": "MedicalCode",
"code": "D065693",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.349"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Inducteurs du cytochrome P-450 CYP2C9",
"alternateName": "Cytochrome P-450 CYP2C9 Inducers",
"code": {
"@type": "MedicalCode",
"code": "D065698",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Miklós Poór",
"url": "https://questionsmedicales.fr/author/Mikl%C3%B3s%20Po%C3%B3r",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacology, Faculty of Pharmacy, University of Pécs, Rókus u. 2, Pécs H-7624, Hungary; Lab-on-a-Chip Research Group, János Szentágothai Research Centre, University of Pécs, Ifjúság útja 20, Pécs H-7624, Hungary. Electronic address: poor.miklos@pte.hu."
}
},
{
"@type": "Person",
"name": "Jian-Ping Cai",
"url": "https://questionsmedicales.fr/author/Jian-Ping%20Cai",
"affiliation": {
"@type": "Organization",
"name": "The Key laboratory of Geriatrics, Beijing Institute of Geriatrics, Beijing Hospital, National Center of Gerontology, National Health Commission, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P. R. China."
}
},
{
"@type": "Person",
"name": "Slávka Bodnárová",
"url": "https://questionsmedicales.fr/author/Sl%C3%A1vka%20Bodn%C3%A1rov%C3%A1",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacology, Faculty of Pharmacy, University of Pécs, Rókus u. 2, Pécs H-7624, Hungary; Lab-on-a-Chip Research Group, János Szentágothai Research Centre, University of Pécs, Ifjúság útja 20, Pécs H-7624, Hungary."
}
},
{
"@type": "Person",
"name": "Eszter Fliszár-Nyúl",
"url": "https://questionsmedicales.fr/author/Eszter%20Flisz%C3%A1r-Ny%C3%BAl",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacology, Faculty of Pharmacy, University of Pécs, Rókus u. 2, Pécs H-7624, Hungary; Lab-on-a-Chip Research Group, János Szentágothai Research Centre, University of Pécs, Ifjúság útja 20, Pécs H-7624, Hungary."
}
},
{
"@type": "Person",
"name": "Jian Liu",
"url": "https://questionsmedicales.fr/author/Jian%20Liu",
"affiliation": {
"@type": "Organization",
"name": "The Key laboratory of Geriatrics, Beijing Institute of Geriatrics, Beijing Hospital, National Center of Gerontology, National Health Commission, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P. R. China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "The effect of microbiome composition on impulsive and violent behavior: A systematic review.",
"datePublished": "2022-12-20",
"url": "https://questionsmedicales.fr/article/36549572",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.bbr.2022.114266"
}
},
{
"@type": "ScholarlyArticle",
"name": "Choices between money and hyper-palatable food: Choice impulsivity and eating behavior.",
"datePublished": "2022-06-23",
"url": "https://questionsmedicales.fr/article/35737556",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1037/hea0001185"
}
},
{
"@type": "ScholarlyArticle",
"name": "Difficulties in impulse control in adolescents with problematic use of the internet and self-injurious behaviors.",
"datePublished": "2022-10-21",
"url": "https://questionsmedicales.fr/article/37732862",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.psychres.2022.114919"
}
},
{
"@type": "ScholarlyArticle",
"name": "Neural correlates of impulsive compulsive behaviors in Parkinson's disease: A Japanese retrospective study.",
"datePublished": "2022-12-28",
"url": "https://questionsmedicales.fr/article/36586362",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.nicl.2022.103307"
}
},
{
"@type": "ScholarlyArticle",
"name": "Distinct neurocognitive fingerprints reflect differential associations with risky and impulsive behavior in a neurotypical sample.",
"datePublished": "2023-07-21",
"url": "https://questionsmedicales.fr/article/37479846",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-023-38991-0"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Actions chimiques et utilisations",
"item": "https://questionsmedicales.fr/mesh/D020164"
},
{
"@type": "ListItem",
"position": 3,
"name": "Actions pharmacologiques",
"item": "https://questionsmedicales.fr/mesh/D020228"
},
{
"@type": "ListItem",
"position": 4,
"name": "Mécanismes moléculaires de l'action pharmacologique",
"item": "https://questionsmedicales.fr/mesh/D045504"
},
{
"@type": "ListItem",
"position": 5,
"name": "Inducteurs des enzymes du cytochrome P-450",
"item": "https://questionsmedicales.fr/mesh/D065693"
},
{
"@type": "ListItem",
"position": 6,
"name": "Inducteurs du cytochrome P-450 CYP2C9",
"item": "https://questionsmedicales.fr/mesh/D065698"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Inducteurs du cytochrome P-450 CYP2C9 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Inducteurs du cytochrome P-450 CYP2C9",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-07",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Inducteurs du cytochrome P-450 CYP2C9",
"description": "Comment identifier un inducteur du CYP2C9 ?\nQuels tests sont utilisés pour évaluer l'activité du CYP2C9 ?\nQuels signes indiquent une induction du CYP2C9 ?\nComment les interactions médicamenteuses sont-elles diagnostiquées ?\nQuels médicaments sont souvent des inducteurs du CYP2C9 ?",
"url": "https://questionsmedicales.fr/mesh/D065698?mesh_terms=Impulsive+Behavior#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Inducteurs du cytochrome P-450 CYP2C9",
"description": "Quels symptômes peuvent indiquer une induction du CYP2C9 ?\nComment l'induction du CYP2C9 affecte-t-elle les médicaments ?\nQuels effets secondaires peuvent survenir ?\nLes symptômes varient-ils selon les patients ?\nQuels signes cliniques sont observés ?",
"url": "https://questionsmedicales.fr/mesh/D065698?mesh_terms=Impulsive+Behavior#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Inducteurs du cytochrome P-450 CYP2C9",
"description": "Comment prévenir l'induction du CYP2C9 ?\nLes patients doivent-ils informer leur médecin des médicaments ?\nDes tests génétiques peuvent-ils aider à la prévention ?\nComment éduquer les patients sur les inducteurs ?\nLes changements de mode de vie peuvent-ils aider ?",
"url": "https://questionsmedicales.fr/mesh/D065698?mesh_terms=Impulsive+Behavior#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Inducteurs du cytochrome P-450 CYP2C9",
"description": "Comment ajuster le traitement en cas d'induction du CYP2C9 ?\nQuels médicaments peuvent être utilisés pour contrer l'induction ?\nComment surveiller l'efficacité du traitement ?\nQuels sont les risques d'un traitement inapproprié ?\nLes changements de traitement doivent-ils être rapides ?",
"url": "https://questionsmedicales.fr/mesh/D065698?mesh_terms=Impulsive+Behavior#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Inducteurs du cytochrome P-450 CYP2C9",
"description": "Quelles complications peuvent résulter de l'induction du CYP2C9 ?\nComment l'induction affecte-t-elle la santé globale ?\nLes complications sont-elles réversibles ?\nQuels sont les risques à long terme ?\nComment gérer les complications liées à l'induction ?",
"url": "https://questionsmedicales.fr/mesh/D065698?mesh_terms=Impulsive+Behavior#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Inducteurs du cytochrome P-450 CYP2C9",
"description": "Quels sont les principaux facteurs de risque d'induction ?\nLa génétique joue-t-elle un rôle dans l'induction ?\nLes habitudes alimentaires influencent-elles l'induction ?\nLes maladies hépatiques augmentent-elles le risque ?\nLes interactions médicamenteuses sont-elles un facteur de risque ?",
"url": "https://questionsmedicales.fr/mesh/D065698?mesh_terms=Impulsive+Behavior#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment identifier un inducteur du CYP2C9 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'identification se fait par l'analyse des antécédents médicamenteux et des tests de métabolisme."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'activité du CYP2C9 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de pharmacogénétique et des dosages de médicaments peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une induction du CYP2C9 ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une diminution de l'efficacité des médicaments métabolisés par CYP2C9 peut être un signe."
}
},
{
"@type": "Question",
"name": "Comment les interactions médicamenteuses sont-elles diagnostiquées ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles sont diagnostiquées par l'examen des interactions dans les bases de données médicales."
}
},
{
"@type": "Question",
"name": "Quels médicaments sont souvent des inducteurs du CYP2C9 ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments comme la rifampicine et certains anticonvulsivants sont des inducteurs."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer une induction du CYP2C9 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes de sous-dosage des médicaments, comme une douleur persistante, peuvent apparaître."
}
},
{
"@type": "Question",
"name": "Comment l'induction du CYP2C9 affecte-t-elle les médicaments ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut réduire l'efficacité des médicaments, entraînant des symptômes de la maladie sous-jacente."
}
},
{
"@type": "Question",
"name": "Quels effets secondaires peuvent survenir ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des effets secondaires liés à un sous-dosage, comme des convulsions, peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon les patients ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent varier en fonction de la génétique et des médicaments pris."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques sont observés ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes cliniques comme une réponse insuffisante au traitement peuvent être observés."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'induction du CYP2C9 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter les inducteurs connus et surveiller les interactions médicamenteuses est essentiel."
}
},
{
"@type": "Question",
"name": "Les patients doivent-ils informer leur médecin des médicaments ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, informer le médecin de tous les médicaments pris aide à prévenir les interactions."
}
},
{
"@type": "Question",
"name": "Des tests génétiques peuvent-ils aider à la prévention ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des tests génétiques peuvent identifier les patients à risque d'induction enzymatique."
}
},
{
"@type": "Question",
"name": "Comment éduquer les patients sur les inducteurs ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'éducation sur les médicaments inducteurs et leurs effets est cruciale pour la prévention."
}
},
{
"@type": "Question",
"name": "Les changements de mode de vie peuvent-ils aider ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des changements de mode de vie, comme une alimentation saine, peuvent aider."
}
},
{
"@type": "Question",
"name": "Comment ajuster le traitement en cas d'induction du CYP2C9 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il peut être nécessaire d'augmenter la dose des médicaments affectés pour compenser."
}
},
{
"@type": "Question",
"name": "Quels médicaments peuvent être utilisés pour contrer l'induction ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des inhibiteurs du CYP2C9 peuvent être utilisés pour réduire l'induction enzymatique."
}
},
{
"@type": "Question",
"name": "Comment surveiller l'efficacité du traitement ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "La surveillance se fait par des tests réguliers des niveaux de médicaments dans le sang."
}
},
{
"@type": "Question",
"name": "Quels sont les risques d'un traitement inapproprié ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un traitement inapproprié peut entraîner des complications graves, comme des crises épileptiques."
}
},
{
"@type": "Question",
"name": "Les changements de traitement doivent-ils être rapides ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les changements doivent être faits prudemment pour éviter des effets indésirables."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent résulter de l'induction du CYP2C9 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme des crises convulsives ou une résistance au traitement peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment l'induction affecte-t-elle la santé globale ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut compromettre la santé en rendant les traitements moins efficaces, aggravant les maladies."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être réversibles avec un ajustement approprié du traitement."
}
},
{
"@type": "Question",
"name": "Quels sont les risques à long terme ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les risques à long terme incluent des maladies chroniques dues à un traitement inefficace."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications liées à l'induction ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion implique un suivi régulier et des ajustements de traitement basés sur les symptômes."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque d'induction ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'utilisation de certains médicaments, l'alcool et des maladies hépatiques."
}
},
{
"@type": "Question",
"name": "La génétique joue-t-elle un rôle dans l'induction ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des variations génétiques peuvent influencer l'activité du CYP2C9 et son induction."
}
},
{
"@type": "Question",
"name": "Les habitudes alimentaires influencent-elles l'induction ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines habitudes alimentaires, comme la consommation de pamplemousse, peuvent influencer l'induction."
}
},
{
"@type": "Question",
"name": "Les maladies hépatiques augmentent-elles le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les maladies hépatiques peuvent augmenter le risque d'induction du CYP2C9."
}
},
{
"@type": "Question",
"name": "Les interactions médicamenteuses sont-elles un facteur de risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les interactions entre médicaments peuvent augmenter le risque d'induction enzymatique."
}
}
]
}
]
}
Department of Pharmacology, Faculty of Pharmacy, University of Pécs, Rókus u. 2, Pécs H-7624, Hungary; Lab-on-a-Chip Research Group, János Szentágothai Research Centre, University of Pécs, Ifjúság útja 20, Pécs H-7624, Hungary. Electronic address: poor.miklos@pte.hu.
Publications dans "Inducteurs du cytochrome P-450 CYP2C9" :
The Key laboratory of Geriatrics, Beijing Institute of Geriatrics, Beijing Hospital, National Center of Gerontology, National Health Commission, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P. R. China.
Publications dans "Inducteurs du cytochrome P-450 CYP2C9" :
Department of Pharmacology, Faculty of Pharmacy, University of Pécs, Rókus u. 2, Pécs H-7624, Hungary; Lab-on-a-Chip Research Group, János Szentágothai Research Centre, University of Pécs, Ifjúság útja 20, Pécs H-7624, Hungary.
Publications dans "Inducteurs du cytochrome P-450 CYP2C9" :
Department of Pharmacology, Faculty of Pharmacy, University of Pécs, Rókus u. 2, Pécs H-7624, Hungary; Lab-on-a-Chip Research Group, János Szentágothai Research Centre, University of Pécs, Ifjúság útja 20, Pécs H-7624, Hungary.
Publications dans "Inducteurs du cytochrome P-450 CYP2C9" :
The Key laboratory of Geriatrics, Beijing Institute of Geriatrics, Beijing Hospital, National Center of Gerontology, National Health Commission, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P. R. China.
Publications dans "Inducteurs du cytochrome P-450 CYP2C9" :
Cardiovascular Department, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P. R. China.
Publications dans "Inducteurs du cytochrome P-450 CYP2C9" :
Cardiovascular Department, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P. R. China.
Publications dans "Inducteurs du cytochrome P-450 CYP2C9" :
Cardiovascular Department, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P. R. China.
Publications dans "Inducteurs du cytochrome P-450 CYP2C9" :
The Key laboratory of Geriatrics, Beijing Institute of Geriatrics, Beijing Hospital, National Center of Gerontology, National Health Commission, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P. R. China.
Publications dans "Inducteurs du cytochrome P-450 CYP2C9" :
The impact of the microbiome on brain function and behavior has recently become an important research topic. We searched for a link between the gut microbiome and impulsive and violent behavior. We fo...
Choice impulsivity may influence eating behavior. The study tested whether choice impulsivity, termed delay discounting, may be related to food generally, or may be specific to hyper-palatable foods (...
Participants (...
There were no significant differences in discounting of HPF and non-HPF in single commodity conditions (Mean ln[k] difference = .40,...
Choice impulsivity may be specific to foods that are hyper-palatable. Results suggest that individuals with excess HPF intake, higher HPF craving, and higher BMIs may exhibit a general tendency toward...
Problematic use of the internet (PUI) and self-injurious behaviors (SIB) associate in adolescents and both relate to impulsivity. However, studies have not examined whether difficulties in impulse con...
Impulsive compulsive behaviors (ICBs) often disturb patients with Parkinson's Disease (PD), of which impulse control disorder (ICD) and dopamine dysregulation syndrome (DDS) are two major subsets. The...
To identify the cortico-striatal network primarily involved in ICB and the differences in these networks between patients with ICD and DDS using structural and resting-state functional magnetic resona...
Patients with PD were recruited using data from a previous cohort study and divided into those with ICB (ICB group) and without ICB (non-ICB group) using the Japanese version of the Questionnaire for ...
We found no significant differences in gray matter volumebetween the ICB and non-ICB groups or between patients with ICD and those with DDS. Compared with the non-ICB group, the FC of the right NAcc i...
The functionally altered network between the right NAcc and ventromedial prefrontal cortex was associated with ICB in PD. In addition, the surrounding cortico-striatal networks may differentiate the b...
Engagement in risky and impulsive behavior has long been associated with deficits in neurocognition. However, we have a limited understanding of how multiple subfunctions of neurocognition co-occur wi...
Anorexia nervosa (AN) is a severe psychiatric disorder marked by extreme weight control behaviors and significant impacts on physical and psychosocial health. This study explores the relationship betw...
Behavioral inhibition/activation systems (BIS/BAS) and impulsivity are associated with problematic smartphone use (PSU). However, no studies to date have explored how the subdomains of BIS/BAS and the...
A regularized partial correlation network of PSU, BIS/BAS, and impulsivity communities was estimated to investigate the connections between variables and determine the expected influence and bridge ex...
In addition to connections within each community, network analysis revealed that there were connections between different communities, especially connections to PSU. I2 "motor impulsivity" was strongl...
The connections between the subdomains of BIS/BAS and the components of PSU and between the dimensions of impulsivity and the components of PSU may be particularly important in the development and mai...
The present study investigated whether an unhealthy diet and other lifestyle behaviors may modify the genetic susceptibility to impulsivity. A total of 33,047 participants (mean age = 42.1 years, 59.8...
The Impulsive Behavior Short Scale-8 (I-8) measures the psychological construct of impulsivity with four subscales comprising two items each (completion time < 1 min). The aim of the present study was...
Impulsivity represents a risk factor for patients with binge-eating disorder, and we therefore investigated the treatment process of impulsive behaviors including binge-eating episodes in the randomiz...